HI-TECH PHARMACAL (NASDAQ:HITK)

View All ReportsStreetInsider.com Reports on HITK

Dec 23, 2009 09:34 AM Bank of America Initiates Coverage on Hi-Tech Pharmacal (HITK) with an Underperform

Dec 9, 2009 10:20 AM Morning Movers 12/09: RNWK, EFJI, S, HITK, VCI, COO Higher; ECA, RGEN, MOV, MW, PLAB Lower

Dec 9, 2009 08:19 AM Hi-Tech Pharmacal (HITK) Reports Strong Q2 Earnings

Sep 10, 2009 11:30 AM FTN Equity Downgrades Hi-Tech Pharmacal (HITK) from Buy

Sep 9, 2009 12:14 PM Unusual 11 Mid-Day Movers 9/9: ENCO, VVUS, CLZR, HITK, DPTR Higher; OPXA, LRN, ROSG, ELOS Lower

View All Press ReleasesCompany Press Releases on HITK

Jan 7, 2010 08:00AM Hi-Tech Pharmacal's ECR Subsidiary to Launch a New Dermatitis Treatment

StreetInsider Reports on HITK by Category

• Analyst Ratings
• Mergers and Acquisitions
• Earnings
• Guidance
• Stock Buybacks
• Dividends
• Retail Sales
• Management Changes
• Insider Trades
• View More Categories

View All BlogsBlogs on HITK

Jan 18, 2010 02:26 AM 20 'Babies with Bathwater' and 7 'Dogs with Fleas' Stocks for the Week

Oct 26, 2009 03:15 AM 19 'Babies with Bathwater' and 1 'Dog with Fleas' Stocks for the Week

Sep 10, 2009 04:47 AM 16 Breakout Stocks on Unusually High Volume

Sep 9, 2009 04:29 PM Closing Update for Wednesday, Sept. 9

Aug 28, 2009 04:49 AM Mylan: Generic Drugmaker with a Strong Portfolio

View All FilingsSEC Filings on HITK

Feb 8, 2010 10:36AM Form SC 13G/A HI TECH PHARMACAL CO Filed by: DIMENSIONAL FUND ADVISORS LP

Jan 29, 2010 02:52PM Form SC 13G HI TECH PHARMACAL CO Filed by: BlackRock Inc.

Jan 27, 2010 03:10PM Form SC 13G/A HI TECH PHARMACAL CO Filed by: ROYCE & ASSOCIATES LLC

Jan 19, 2010 10:46AM Form 4 HI TECH PHARMACAL CO For: Jan 15 Filed by: SELTZER REUBEN

Jan 7, 2010 04:01PM Form 4 HI TECH PHARMACAL CO For: Jan 05 Filed by: PETERS WILLIAM J

Comments on recent HITK articles

JM
on Dec 29, 2009
at 10:37 AM HITK & Stock Price Performance Since the BoA analyst has come out with his opinion the stock has touched a new 52 week high today!. Great call analyst whoever you are!
Article: Bank of America Initiates Coverage on Hi-Tech Pharmacal (HITK) with an Underperform

Chuck Irwin
on Dec 24, 2009
at 11:39 AM HITK I don't think the analyst is wrong for the following reasons: History has shown the the market will correct the firt two weeks of Jan 2010, HITK should do go a week before and a week after earning report, however after the last earnings report I have not seen any analyst put out a recomendation. The stock has a book value of $8.00 and unless they report some good news I expect the stock to drift doqn to the $23.00 area maybe a little lower.
Article: Bank of America Initiates Coverage on Hi-Tech Pharmacal (HITK) with an Underperform

GJ
on Dec 23, 2009
at 11:33 PM HITK I think the analyst is dead wrong on HITK. I certainly think HITK looks very good to me.
Article: Bank of America Initiates Coverage on Hi-Tech Pharmacal (HITK) with an Underperform

toddschaus
on Sep 15, 2009
at 08:46 PM HITK underpriced and deserving further analysis I am a CPA veteran and stock analysis enthusiast that has been actively researching and following HITK for a long time. Sales, margins, and net profits for the company are growing off the charts over the past 6 months. They appear to have quietly arrived in the generic drug industry as a competitor on a new level. The company's trailing PE of 15 includes $1.5M earnings for the 2nd and 3rd qtrs of the prior fiscal year........but these amounts don't appear very relevant considering consecutive record breaking quarters of $5M and $8M earnings for the more recent 4th qtr of last year and the 1st qtr of the current fiscal year. I have been listening and participating on the company quarterly conference calls and weighing their comments about the future. I believe they will be reporting $8M+ earnings for the next two qtrs (i.e. the 2nd & 3rd qtr of this fiscal year). Note - the 2nd & 3rd qtrs are historically the company's best qtrs considering it is flu season. Without considering other positive factors.....down economy (read more $$$ to be spent on generics), an aging population base, growth possibility for a company breaking out of its shell, I see the company as underpriced and the stock hitting 40-50 (still at a 15 PE) in the next 6 months as the upcoming 2nd and 3rd qtr earnings are released. What are your thoughts? Regards, Todd Schaus
Article: Hi-Tech Pharmacal (HITK) Reports Surge in Q1 Sales and EPS

toddschaus
on Sep 15, 2009
at 08:44 PM HITK underpriced and deserving further analysis I am a CPA veteran and stock analysis enthusiast that has been actively researching and following HITK for a long time. Sales, margins, and net profits for the company are growing off the charts over the past 6 months. They appear to have quietly arrived in the generic drug industry as a competitor on a new level. The company's trailing PE of 15 includes $1.5M earnings for the 2nd and 3rd qtrs of the prior fiscal year........but these amounts don't appear very relevant considering consecutive record breaking quarters of $5M and $8M earnings for the more recent 4th qtr of last year and the 1st qtr of the current fiscal year. I have been listening and participating on the company quarterly conference calls and weighing their comments about the future. I believe they will be reporting $8M+ earnings for the next two qtrs (i.e. the 2nd & 3rd qtr of this fiscal year). Note - the 2nd & 3rd qtrs are historically the company's best qtrs considering it is flu season. Without considering other positive factors.....down economy (read more $$$ to be spent on generics), an aging population base, growth possibility for a company breaking out of its shell, I see the company as underpriced and the stock hitting 40-50 (still at a 15 PE) in the next 6 months as the upcoming 2nd and 3rd qtr earnings are released. What are your thoughts? Regards, Todd Schaus
Article: Hi-Tech Pharmacal (HITK) Reports Mixed Q3 Earnings

Comments on HITK

No comments are currently available.

Name

Subject

Body

Verification can't see the text?
click here to refresh the image.
what's this?